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1. Introduction 
The study of a number of synthetic analogs of 
arginine vasopressin (AVP) has helped to delineate 
those structural changes of the AVP molecule which 
give rise to enhancement of antidiuretic/vasopressor 
(A/V) specificity [l-9] . AVP has the following 
structure in which the numbers indicate the position 
of the individual amino acid residues. 
Cy8-Tyr-Phe-Gln-Asn-Cyi-Pro-Arg-Gly-NH2 
123456789 
The individual structural alterations of AVP which 
bring about enhancement of A/V specificity are: 
(a) deamination of position one [3] ; (b) enhance- 
ment of lipophilicity at position 4 [ 1,8] and (c) 
substitution of D- for L-arginine at position 8 [ 51. 
When all three changes were incorporated into one 
molecule the resulting peptide [ 1 deamino-4valine] - 
8-D-arginine vasopressin (dVDAVP) was found to 
be the most highly specific antidiuretic peptide ever 
reported [lo] . dVDAVP has undetectable vasopres- 
sor activity, antidiuretic activity about four times 
that of AVP and an A/V ratio of over 123 000 com- 
pared to 0.9 for AVP. It also exhibits a markedly 
prolonged duration of action similar to that previous- 
ly observed for [ 1 -deamino] -8-D7arginine vasopres- 
sin (DDAVP) [7] . 
The present communiation summarizes our sub- 
sequent separately reported findings on the relative 
effects of these structural changes in contributing 
to (1) enhanced antidiuretic specificity [ 1 I] and (2) 
North-Holland Publishing Company - Amsterdam 
prolonged antidiuresis [ 121. We have found that 
antidiuretic specificity is influenced in the following 
order of decreasing effectiveness (c) >> (b) > (a). 
Duration of antidiuresis is due solely to (a) and is not 
at all influenced by (c). Structural change (b) alone 
has no effect on duration of action but in combination 
with (a) it appears to further prolong the persistence 
brought about by (a) alone. These and related stu- 
dies may provide new insight into the structural spe- 
cifications of AVP receptors, into the mechanisms 
that terminate antidiuretic responses and to the 
design of AVP peptides possessing desired biological 
properties of potential clinical value. 
2. Materials aud methods 
The antidiuretic peptides used in our studies 
[ 11 ,121 are listed in table 1. Some were donated 
[ 121 but most were synthesized in our laboratories 
with the use of the solid phase method [ 131 follow- 
ing the procedure used for the synthesis of oxytocin 
[14] AVP [I] and analogs [2,10,11]. The bioassay 
procedures are described in detail elsewhere [ 11 ,121. 
3. Results and discussion 
3.1. Antidiuretic specificity 
The data in table 1 support the following conclu- 
sions in regard to the relative effects of the three 
structural changes in bringing about enhancement 
of antidiuretic specificity. 
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3.1.1. Deamination at position 1 
This change usually but not always leads to a 
modest enhancement of antidiuretic specificity pri- 
marily by increasing antidiuretic activity in all the 
analogs studied to date. The effect of deamination 
on vasopressor activity is not at all constant. It varies 
from peptide pair to peptide pair; it may remain 
unchanged, increase or decrease. 
3.1.2. Introduction of lipophilic amino acids in the 
Qposition 
Antidiuretic specificity is increased in all cases 
when compared to the 4glutamine compound. This 
is due primarily to a reduction of vasopressor activity 
and in the case of the valine and a-amino butyric 
acid analogs by either an increase in antidiuretic 
activity or a retention of the same level of activity 
as the parent 4glutamine containing peptide. 
3.1.3. D-Arginine substitution 
This is by far the single most important structural 
change leading to antidiuretic specificity. Earlier 
reports in the literature tended to obscure this fact 
[6,7] . The A/V values for DAVP and dDAVP were 
reported as only 4 and 79, respectively [6]. These 
low values probably resulted from the presence of 
minor but critical (from the biological standpoint) 
amounts of L-arginine in the synthetic peptides. The 
enhancement of antidiuretic specificity is brought 
about in all cases of D-arginine substitution by a 
dramatic reduction is vasopressor activities with the 
antidiuretic potencies, remaining virtually unchang- 
ed. 
That enhancement of lipophilicity at position 4 
plays a greater role than deamination at position 1 
in leading to increased specificity can be ascertain- 
ed from series (c) (table 1). Thus the A/V value of 
238 for DAVP is increased to 17 650 in VDAVP as 
compared to only 2000 for dDAVP. The cumulative 
effect of all three structural modifications is further 
demonstrated by the essentially infinite A/V value 
for dVDAVP. From peptides studied to date the 
relative contributions of the changes in the AVP 
molecule which give rise to enhanced antidiuretic 
specificity are in the following decreasing order: 
8-D-Arginine substitution >> lipophilicity at 
position 4 > deamination at position 1. Perhaps the 
most striking feature to emerge from these specificity 
studies is the contrast in discriminatory characteristics 
between the antidiuretic and vasopressor eceptors. 
The former can tolerate the aforementioned changes 
in three widely separated areas of the molecule i.e. 
in positions I,4 and 8 while the latter, although tolerat, 
ing the changes in positions 1 and 4 to a somewhat 
lesser degree, are extremely sensitive to the change of 
optical configuration of the arginine residue at posi- 
tion 8. The vasopressor eceptors have thus a definite 
requirement for an L-amino acid at position 8 in AVP. 
3.2. Duration of antidiuresis 
Studies on DI rats show clearly that deamination 
of vasopressin analogs which have arginine at posi- 
tion 8 is the single molecular change that has the 
greatest effect on duration of antidiuretic action (fig. 
1). Substitution of a more hydrophobic amino acid 
residue for the 4glutamine in deamino analogs of AVP 
appears to prolong action further (fig. 1). Such sub- 
stitution in the absence of deamination, however, 
appears to have little influence on duration of action. 
The peptides among those tested that have the longest 
action are dTAVP, dAAVP, dVAVP and dVDAVP 
(fig. 1). Substitution of D-arginine for the 8-Larginine 
has little influence on the duration of action in DI 
rats (fig. 1). 
The influence of deamination on the persistence 
of antidiuretic action is evidently dependent, at least 
in part, on the nature of the amino acid in the 8- 
position. Prolongation of action by deamination is 
d 0 
I 3 IO 30 100 300 
Dose. W/k9 
Fig. 1. Duration of antidiuretic responses by DI (diabetes 
insipidus) rats to I-arginine and 8-lysine analogs of vasopres- 
sin. The ‘duration’ was considered the number of hours 
during which urine flow remained less than 50% of the 
control rate for each rat [ 121. Mean control, V=3.26*0.47 
(SD) ml/100 g/hr. Closed circles indicate mean responses to 
deaminated analogs. Vertical lines represent SE’s. See table 
1 for definitions of abbreviations. 
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marked and highly consistent among all the analogs 
tested containing D- or L-arginine but it is less 
pronounced and more variable if other basic amine 
acids are substituted in the &position [ 121. Deamino- 
lysine-vasopresin, deamino-homoarginine-vasopressin, 
and deamino-homolysine-vasopressin have more pro- 
longed effects than their aminated counterparts but 
the antidiuresis they produce decays more rapidly 
than that seen in response to deamino-8arginine ana- 
logs [ 121. Deamino-mesotocin does have a prolonged 
action when given in massive doses, while the response 
to deaminooxytocin does not persist [ 121. We have 
speculated [ 121 that the persistent action of deamino 
AVP peptides derives primarily from their resistance 
to metabolic degradation. This contention has been 
supported by the observation that such analogs are 
resistant to enzymatic degradation by soluble renal 
enzymes in vitro [ 151 . 
Further studies on the correlation between the 
persistance of action of AVP analogs in vivo with 
their susceptibility to enzymatic inactivation in vitro 
can provide a useful approach to the localization and 
characterization of the enzymes that terminate the 
actions of antidiuretic hormones. Furthermore the 
study of these and related analogs of AVP may lead 
to the design of peptides possessing (a) anti-AVP 
characteristics and (b) peptidea possessing enhanced 
vasopressor specificity. 
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